News>Press Releases
Boan Biotech Publishes Research Results for CEA/CD3 Bispecific Antibody in Antibody Therapeutics
June 24,2021
Luye Pharma Group’s subsidiary Boan Biotech recently published research results for its innovative in-house bispecific antibody BA1202 (CEA/CD3 bispecific T-cell engager) in Antibody Therapeutics.
 

Screenshot of the article (image credit: Antibody Therapeutics)

Published by Oxford University Press, Antibody Therapeutics is a peer-reviewed journal under the Chinese Antibody Society. The journal provides a forum for publicizing the latest advances in the global R&D and commercialization of therapeutic antibodies.

As a tumor biomarker and tumor associated antigen, CEA (Carcinoembryonic antigen) is highly expressed in colorectal cancer, gastric cancer, pancreatic cancer, lung cancer, breast cancer and other solid tumors, and its expression correlates with disease progression.

T cell engager antibodies that are designed to target tumor antigens and T cell CD3 are one of the most active fields in the development of bispecific antibodies. They can effectively kill tumor cells expressing tumor-associated antigens, increase the infiltration of immune cells in tumor tissues, and convert cold tumors into hot tumors. If combined with immune checkpoint inhibitors, it can improve efficacy especially for cold tumors.

However, the current development of CD3 antibodies is still facing many challenges, including the toxicity of the cytokine storm caused by high affinity CD3 binding of T cells, and the short half-life of early-approved antibodies in the human body.

To make the CEA-CD3 bispecific antibody, Boan Biotech scientists in the Boston R&D center adopted a new symmetrical butterfly format that retains the Fc region with Fc silencing mutations. This antibody format exhibits bivalent binding to tumor antigen and monovalent binding to CD3 on T cells, which is critical in minimizing target independent T cell activation. Importantly, the team has successfully optimized CD3 affinity to reduce cytokine release.

The highlights of the article include:

· While binding affinity to CD3 is reduced, it does not affect the killing activity against target cells, but secretion of cytokines is greatly reduced. Therefore, it is expected to reduce CRS toxicity.
· It has shown efficacy in the colorectal cancer model, and complete response was observed. In addition, it showed a clear dose-dependent anti-tumor activity with anti-tumor activity at 0.1 mg/kg.
· Compared with other CEA/CD3 antibody drugs under development, our CEA-CD3 showed stronger in vitro activity and in vivo efficacy (data not yet published).
· There was a synergistic anti-tumor effect with anti-PD-L1 Atezolizumab; this was accompanied by a substantial increase in T cell infiltration in the tumor.
· The CEA-CD3 antibody shows high specificity in binding to certain tumor tissues but not to normal tissues in the IHC staining.
 

 
Dr. Li Zhou, the corresponding author of the article and VP of Antibody Research and Cell Therapy of Boan Biotech, added: "We have established a unique CD3 bispecific antibody platform. Compared with similar products that are under development, our CEA-CD3 bispecific antibody demonstrated strong efficacy in vivo and reduced cytokine release. We will accelerate product development in the hope of providing effective and safe treatment options for cancer patients as soon as possible."

The Boan Biotech R&D Center located in Boston USA develops antibody and cell therapy with a focus on cutting-edge technologies. It has a unique bispecific T-cell engager technology platform and a non-viral vector CAR-T platform. An application for patent protection has been filed for the former, while the latter has produced cell therapy products that use non-viral vectors for CAR-T for late stage solid tumors. The center is also exploring novel off-the-shelf CAR-T and regulatable CAR-T, to develop safer, effective and affordable products for patients.
 
###
 
About Boan Biotech

As a subsidiary of Luye Pharma Group, Boan Biotech is a fully integrated biopharmaceutical company that specializes in therapeutic antibody development, manufacturing and commercialization with a focus on oncology, immunology, pain, and endocrine diseases. Boan Biotech's antibody discovery work is based on three technology platforms: Human Antibody Transgenic Mouse and Phage Display Technology, Bispecific T-cell Engager Technology, and ADC Technology. Through leveraging its efficient and innovative capabilities, the company has developed more than 10 innovative antibody product candidates with international intellectual property protection, and 8 biosimilar product candidates, one of which – 博优诺® (Bevacizumab Injection) – has been launched in China.

Boan Biotech has expertise in the full industry chain: antibody generation, lead optimization, cell line development, process development, technology transfer, pilot production, and commercial manufacturing. The company is also actively exploring other cutting-edge technologies. Its cell therapy products use non-viral vectors for CAR-T for late stage solid tumors. Boan Biotech is also developing novel off-the-shelf CAR-T and regulatable CAR-T, to develop safer, effective and affordable products for patients. Outside of China, Boan Biotech also pursues biopharmaceutical products development in the US and EU markets. 
 
News>Press Releases
Boan Biotech Publishes Research Results for CEA/CD3 Bispecific Antibody in Antibody Therapeutics
June 24,2021
Luye Pharma Group’s subsidiary Boan Biotech recently published research results for its innovative in-house bispecific antibody BA1202 (CEA/CD3 bispecific T-cell engager) in Antibody Therapeutics.
 

Screenshot of the article (image credit: Antibody Therapeutics)

Published by Oxford University Press, Antibody Therapeutics is a peer-reviewed journal under the Chinese Antibody Society. The journal provides a forum for publicizing the latest advances in the global R&D and commercialization of therapeutic antibodies.

As a tumor biomarker and tumor associated antigen, CEA (Carcinoembryonic antigen) is highly expressed in colorectal cancer, gastric cancer, pancreatic cancer, lung cancer, breast cancer and other solid tumors, and its expression correlates with disease progression.

T cell engager antibodies that are designed to target tumor antigens and T cell CD3 are one of the most active fields in the development of bispecific antibodies. They can effectively kill tumor cells expressing tumor-associated antigens, increase the infiltration of immune cells in tumor tissues, and convert cold tumors into hot tumors. If combined with immune checkpoint inhibitors, it can improve efficacy especially for cold tumors.

However, the current development of CD3 antibodies is still facing many challenges, including the toxicity of the cytokine storm caused by high affinity CD3 binding of T cells, and the short half-life of early-approved antibodies in the human body.

To make the CEA-CD3 bispecific antibody, Boan Biotech scientists in the Boston R&D center adopted a new symmetrical butterfly format that retains the Fc region with Fc silencing mutations. This antibody format exhibits bivalent binding to tumor antigen and monovalent binding to CD3 on T cells, which is critical in minimizing target independent T cell activation. Importantly, the team has successfully optimized CD3 affinity to reduce cytokine release.

The highlights of the article include:

· While binding affinity to CD3 is reduced, it does not affect the killing activity against target cells, but secretion of cytokines is greatly reduced. Therefore, it is expected to reduce CRS toxicity.
· It has shown efficacy in the colorectal cancer model, and complete response was observed. In addition, it showed a clear dose-dependent anti-tumor activity with anti-tumor activity at 0.1 mg/kg.
· Compared with other CEA/CD3 antibody drugs under development, our CEA-CD3 showed stronger in vitro activity and in vivo efficacy (data not yet published).
· There was a synergistic anti-tumor effect with anti-PD-L1 Atezolizumab; this was accompanied by a substantial increase in T cell infiltration in the tumor.
· The CEA-CD3 antibody shows high specificity in binding to certain tumor tissues but not to normal tissues in the IHC staining.
 

 
Dr. Li Zhou, the corresponding author of the article and VP of Antibody Research and Cell Therapy of Boan Biotech, added: "We have established a unique CD3 bispecific antibody platform. Compared with similar products that are under development, our CEA-CD3 bispecific antibody demonstrated strong efficacy in vivo and reduced cytokine release. We will accelerate product development in the hope of providing effective and safe treatment options for cancer patients as soon as possible."

The Boan Biotech R&D Center located in Boston USA develops antibody and cell therapy with a focus on cutting-edge technologies. It has a unique bispecific T-cell engager technology platform and a non-viral vector CAR-T platform. An application for patent protection has been filed for the former, while the latter has produced cell therapy products that use non-viral vectors for CAR-T for late stage solid tumors. The center is also exploring novel off-the-shelf CAR-T and regulatable CAR-T, to develop safer, effective and affordable products for patients.
 
###
 
About Boan Biotech

As a subsidiary of Luye Pharma Group, Boan Biotech is a fully integrated biopharmaceutical company that specializes in therapeutic antibody development, manufacturing and commercialization with a focus on oncology, immunology, pain, and endocrine diseases. Boan Biotech's antibody discovery work is based on three technology platforms: Human Antibody Transgenic Mouse and Phage Display Technology, Bispecific T-cell Engager Technology, and ADC Technology. Through leveraging its efficient and innovative capabilities, the company has developed more than 10 innovative antibody product candidates with international intellectual property protection, and 8 biosimilar product candidates, one of which – 博优诺® (Bevacizumab Injection) – has been launched in China.

Boan Biotech has expertise in the full industry chain: antibody generation, lead optimization, cell line development, process development, technology transfer, pilot production, and commercial manufacturing. The company is also actively exploring other cutting-edge technologies. Its cell therapy products use non-viral vectors for CAR-T for late stage solid tumors. Boan Biotech is also developing novel off-the-shelf CAR-T and regulatable CAR-T, to develop safer, effective and affordable products for patients. Outside of China, Boan Biotech also pursues biopharmaceutical products development in the US and EU markets.